JCM, Vol. 14, Pages 6139: Beyond Traditional Risk Factors: Integrating Epicardial Adipose Tissue into the Comorbidity Landscape of HFpEF
JCM, Vol. 14, Pages 6139: Beyond Traditional Risk Factors: Integrating Epicardial Adipose Tissue into the Comorbidity Landscape of HFpEF Journal of Clinical Medicine doi: 10.3390/jcm14176139 Authors: Marius-Dragoș Mihăilă Bogdan Caloian Florina Iulia Frîngu Diana Andrada Irimie Ioan Alexandru Minciună Dana Pop Epicardial adipose tissue (EAT), the visceral fat layer next to the myocardium, has become […]
Stuck in the middle with you
The middle is a hard place to be. The middle of a thesis or a book can be excruciating. Things are underway, but not finished. The end is in sight, but not yet reached. In the middle, it’s easy to lose faith in the direction you’re travelling. One of my PhD mentors, Dr Diane Mulcahy, […]
My current appetite control stack (what works and what was overhyped)
Been experimenting with natural appetite management for about 8 months now. Tried basically everything so figured id share what actually moved the needle vs what was just expensive placebo. What works: ozzi drink mix – honestly wasnt expecting much because most glp-1 supplements are trash but this one actually helps with evening cravings. mix tastes […]
GLP-1 Agonists for Obesity Tied to Lower Cancer Risks
Among adults with obesity or overweight, GLP-1 receptor agonists are linked to a slightly lower risk for obesity-related cancers overall but a nonsignificant increase in kidney cancer risk. Medscape Medical News
Environmental Benefit Seen With GLP-1 Receptor Agonist Use in Heart Failure
FRIDAY, Aug. 29, 2025 — Patients with heart failure using glucagon-like peptide 1 receptor agonists (GLP-1 RAs) have less carbon dioxide equivalent (CO2e) greenhouse gas (GHG) emissions per patient per year, according to a study presented at the…
Lilly terminates two Phase 2 studies of next-gen oral GLP-1 drug
Eli Lilly has ended two mid-stage trials of an oral GLP-1 drug for obesity, according to updates this week to the US federal clinical trials database. Another Phase 2 study remains
Understanding Medicare’s Prior Approval Pilot Program—and What States Will Be Impacted
Some Medicare recipients are set to experience a new “prior authorization” measure as the Centers for Medicare & Medicaid Services (CMS) trials its much-discussed “Wasteful and Inappropriate Service Reduction (WISeR)” model. The initiative, announced by the CMS in June, will require recipients of Original Medicare to receive prior approval before obtaining access to certain medical […]
GLP-1 Drugs May Cut Risk of Pesky GI Condition
(MedPage Today) — Patients with type 2 diabetes who were treated with GLP-1 receptor agonists were less likely to develop peptic ulcer disease (PUD), a nationwide study found. In an analysis of more than 65,000 patients, GLP-1 users had 44% lower…
How to overcome the biggest barrier to weight loss
After the ordeal of trying to lose weight, the last thing you want is for it all the extra pounds to come creeping back a few months later. But that scenario is very common. The data suggests the odds of keeping lost weight off are against you. Studies of thousands of people over decades show […]
If You’d Invested $1,000 in DexCom 10 Years Ago, Here’s How Much You’d Have Today
Key Points DexCom’s returns over the past decade have been solid, but not quite on par with the market’s. The company has encountered some headwinds in recent years that have sunk its stock price. Despite the challenges, DexCom still has significant growth prospects and benefits from a moat. 10 stocks we like better than DexCom […]